Technology

The DSLT technology has been fully commercially available in the US since February 2025.

Laura Holtz, OD, states that although it is a small part of the cornea, the epithelium plays a vital role that affects refractive surgery recommendations, diagnosis of corneal ectasias, and contact lens warpage.

The Innovation Hub was split into 3 panel discussions on assessing future health through AI-enabled tools, addressing patient workflow challenges through AI, and enhancing treatment through new technologies.

ZinserLab will focus on accelerating the development of imaging technologies in eye care.

CLARUS 700, the advanced retinal imaging system, captures 133 degrees in a single image and up to 267 degrees with multiple images.

The device was developed by Curators’ Distinguished Teaching Professor Carl Bassi and research collaborators Michael Howe and Wayne Garver of the University of Missouri – St Louis.

The partnership aims to accelerate Pangaea’s efforts to address critical care gaps in eye health and systemic disease.

deepeye TPS is designed to close the gap between real-world outcomes and trial data by reducing patient dropout.

In total, 613,690 images used for screening were included in the study.

The system was taught quality standards by being fed more than 1400 images from different parts of the retina taken by adaptive-optics ophthalmoscopy.

Valeda met the primary end point in the US LIGHTSIDE III trial, improving the best corrected visual acuity in patients for 24 months of >5 letters or equivalent to 1 line improvement on the eye chart, according to the company.

Topcon Healthcare launches IDHea, an innovative platform enhancing AI research and ocular data access to improve clinical outcomes in health care, alongside Cascader Limited, which was created in partnership with Moorfields Eye Hospital NHS Foundation Trust and the UCL Institute of Ophthalmology (IoO).

With the acquisition, Topcon Healthcare also assumes RetInSight’s AI algorithms that analyze retinal images to detect and monitor disease.

The survey results included 11,412 patients in the general population and 964 health care providers.

The donation given by the Frances G. Scaife Foundation will aid in the funding of 1-on-1 work and group training sessions

The collaboration allows Topcon to become the exclusive global distributor of Inspire, RadiusXR’s new wearable vision testing platform.

Key parameters captured by the module include disc area, cup area, cup volume, minimal cup depth, maximum cup depth, cup/disc area ratio, rim absence angle, and disc-damage likelihood scale.

The report found that 68% of employees experience digital eye strain symptoms such as blurred vision, eye strain, and dry, itchy eyes, with 59% reporting affects to productivity.

Wearable technology options can meet patient’s goals.

The upgraded Myopia Software Package offers comprehensive screening, ortho-k fitting, and myopia management in one device.

MonacoPro, the next evolution of Monaco from Optos, retains the powerful ultra-widefield SLO and spectral domain imaging while adding additional key product features.

According to a news release from the company, the VR platform “disrupt[s] traditional diagnostic methods by offering an untethered, all-in-one diagnostic solution that includes a variety of tests such as visual field, progression analysis, color sensitivity, and now visual acuity testing.”

Toronto-based Cellview currently designs and manufactures highly performant diagnostic imaging instruments that leverage internal R&D expertise, according to a news release.

The device was created in collaboration with SlitLED and featuring AutoAquire, RemotePilot, and Multi-Slit views.

Now, the VTO platform features 3 different offerings, 2 which are new and 1 which has been updated, according to the company.

The goal of the agreement is to advance Eleva’s current programs into mid- and late-stage clinical development.

C.Rex is the only MGIS technology on the market that allows for fully titratable 180-360 comprehensive intervention.

Results from the study assisted Notal Vision in receiving De Novo authorization from the US FDA for the SCANLY Home OCT in 2024.